NASDAQ : JSPR
Jasper Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.532 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 17.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 17.96M | 20.28M | 20.42M | 17.08M | 16.57M | 11.41M |
| Research & Development | 34.90M | 61.30M | 55.82M | 51.78M | 34.63M | 25.42M |
| Operating Expenses | 52.86M | 81.58M | 76.24M | 68.86M | 51.20M | 36.83M |
| Operating Income | -52.86M | -81.58M | -76.24M | -68.86M | -51.20M | -36.83M |
| Interest & Investment Income | 926.00K | 1.74M | 5.06M | 5.20M | 701.00K | |
| Other Non Operating Income (Expenses) | 22.47M | 6.34M | -88.00K | -821.00K | 7.08M | -3.08M |
| EBT Excluding Unusual Items | -29.47M | -73.50M | -71.27M | -64.48M | -43.41M | -39.91M |
| Merger & Restructuring Charges | -2.30M | -2.30M | ||||
| Other Unusual Items | 18.00K | 5.72M | 9.28M | |||
| Pretax Income | -31.77M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
| Net Income | -31.77M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
| Net Income to Common | -31.77M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
| Shares Outstanding (Basic) | 25.92M | 19.17M | 14.58M | 10.44M | 3.65M | 1.14M |
| Shares Outstanding (Diluted) | 25.92M | 19.17M | 14.58M | 10.44M | 3.65M | 1.14M |
| EPS (Basic) | -1.23 | -3.95 | -4.89 | -6.18 | -10.33 | -26.89 |
| EPS (Diluted) | -1.23 | -3.95 | -4.89 | -6.18 | -10.33 | -26.89 |
| Free Cash Flow | -60.33M | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Free Cash Flow Per Share | -2.33 | -4.03 | -4.33 | -5.01 | -12.73 | -31.69 |
| EBITDA | -52.30M | -80.53M | -74.87M | -67.75M | -50.22M | -36.46M |
| D&A For EBITDA | 561.00K | 1.06M | 1.37M | 1.11M | 975.00K | 377.00K |
| EBIT | -52.86M | -81.58M | -76.24M | -68.86M | -51.20M | -36.83M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.31M | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Cash & Short-Term Investments | 7.31M | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Other Receivables | 250.00K | 913.00K | 548.00K | |||
| Receivables | 250.00K | 913.00K | 548.00K | |||
| Prepaid Expenses | 1.00M | 1.63M | 1.57M | 1.19M | 1.61M | 2.29M |
| Other Current Assets | 2.84M | 4.32M | 2.60M | 615.00K | 960.00K | 289.00K |
| Total Current Assets | 11.57M | 34.65M | 75.81M | 88.94M | 41.73M | 87.83M |
| Property, Plant & Equipment | 188.00K | 604.00K | 2.85M | 4.19M | 5.45M | 4.83M |
| Other Long-Term Assets | 43.00K | 530.00K | 1.24M | 1.76M | 1.18M | 990.00K |
| Total Assets | 11.80M | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Accounts Payable | 2.78M | 6.22M | 4.03M | 4.15M | 1.77M | 3.92M |
| Accrued Expenses | 4.75M | 5.62M | 9.70M | 6.94M | 4.24M | 2.81M |
| Current Portion of Leases | 270.00K | 1.24M | 1.09M | 972.00K | 865.00K | 505.00K |
| Other Current Liabilities | 45.00K | 120.00K | 419.00K | 317.00K | 194.00K | 785.00K |
| Total Current Liabilities | 7.84M | 13.20M | 15.24M | 12.37M | 7.07M | 8.02M |
| Long-Term Leases | 724.00K | 1.81M | 2.79M | 2.38M | ||
| Long-Term Unearned Revenue | 2.26M | 2.26M | 2.26M | 2.26M | 600.00K | |
| Other Long-Term Liabilities | 2.54M | 16.16M | 257.00K | 13.14M | ||
| Total Liabilities | 10.39M | 31.63M | 18.23M | 16.45M | 12.37M | 24.14M |
| Common Stock | 3.00K | 3.00K | 2.00K | 1.00K | 4.00K | |
| Additional Paid-In Capital | 322.01M | 320.82M | 302.54M | 248.04M | 141.12M | 136.96M |
| Retained Earnings | -320.60M | -316.67M | -240.87M | -169.60M | -105.14M | -67.45M |
| Total Common Equity | 1.41M | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
| Shareholders' Equity | 1.41M | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
| Total Liabilities & Equity | 11.80M | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Total Debt | 270.00K | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M |
| Net Cash (Debt) | 7.04M | 27.46M | 69.82M | 84.10M | 34.60M | 81.82M |
| Net Cash Per Share | 0.27 | 1.43 | 4.79 | 8.06 | 9.48 | 71.81 |
| Filing Date Shares Outstanding | 33.27M | 28.00M | 15.02M | 15.06M | 10.94M | 4.95M |
| Total Common Shares Outstanding | 28.08M | 28.00M | 15.02M | 11.16M | 4.62M | 4.95M |
| Working Capital | 3.73M | 21.45M | 60.57M | 76.56M | 34.67M | 79.81M |
| Book Value Per Share | 0.05 | 0.15 | 4.11 | 7.03 | 7.78 | 14.04 |
| Tangible Book Value | 1.41M | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
| Tangible Book Value Per Share | 0.05 | 0.15 | 4.11 | 7.03 | 7.78 | 14.04 |
| Machinery | 1.56M | 2.21M | 2.88M | 2.62M | 2.35M | 1.92M |
| Leasehold Improvements | 2.71M | 2.71M | 2.71M | 2.48M | 2.48M | 2.06M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -31.77M | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
| Depreciation & Amortization | 561.00K | 1.06M | 1.37M | 1.11M | 975.00K | 377.00K |
| Asset Writedown & Restructuring Costs | 1.11M | 1.11M | ||||
| Stock-Based Compensation | 4.27M | 6.71M | 6.62M | 5.21M | 4.09M | 1.05M |
| Other Operating Activities | -21.34M | -5.32M | 491.00K | 976.00K | -12.59M | -6.09M |
| Change in Accounts Receivable | 663.00K | -663.00K | 600.00K | |||
| Change in Accounts Payable | -5.26M | 2.19M | -122.00K | 2.38M | -2.15M | 2.94M |
| Change in Other Net Operating Assets | -7.83M | -7.12M | 306.00K | 2.06M | 2.17M | -1.92M |
| Operating Cash Flow | -60.33M | -77.16M | -62.60M | -52.07M | -45.86M | -33.68M |
| Capital Expenditures | -7.00K | -552.00K | -267.00K | -576.00K | -2.43M | |
| Sale of Property, Plant & Equipment | 80.00K | 12.00K | 20.00K | |||
| Investing Cash Flow | 80.00K | 5.00K | -532.00K | -267.00K | -576.00K | -2.43M |
| Issuance of Common Stock | 28.06M | 34.21M | 47.88M | 101.93M | 55.00K | 236.00K |
| Repurchase of Common Stock | -960.00K | |||||
| Other Financing Activities | 89.98M | |||||
| Financing Cash Flow | 28.06M | 34.21M | 47.88M | 100.97M | 55.00K | 100.97M |
| Net Cash Flow | -32.20M | -42.95M | -15.25M | 48.64M | -46.38M | 64.86M |
| Free Cash Flow | -60.33M | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Free Cash Flow Per Share | -2.33 | -4.03 | -4.33 | -5.01 | -12.73 | -31.69 |
| Levered Free Cash Flow | -39.98M | -47.19M | -39.59M | -30.35M | -29.17M | -22.80M |
| Unlevered Free Cash Flow | -39.98M | -47.19M | -39.59M | -30.35M | -29.17M | -22.80M |
| Change in Working Capital | -13.09M | -4.92M | 184.00K | 5.10M | -649.00K | 1.62M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 16.90M | 51.21M | 320.73M | 88.03M | 22.30M | 388.71M |
| Enterprise Value | 2.01M | 230.30M | -12.82M | -24.79M | 290.81M | |
| Last Close Price | 0.51 | 1.83 | 21.38 | 7.89 | 4.83 | 78.50 |
| PB Ratio | 12.34 | 5.20 | 1.12 | 0.62 | 5.59 | |
| P/TBV Ratio | 12.34 | 5.20 | 1.12 | 0.62 | 5.59 | |
| Debt / Equity Ratio | 0.19 | 0.30 | 0.03 | 0.04 | 0.10 | 0.04 |
| Net Debt / Equity Ratio | -4.99 | -6.62 | -1.13 | -1.07 | -0.96 | -1.18 |
| Net Debt / EBITDA Ratio | 0.14 | 0.34 | 0.93 | 1.24 | 0.69 | 2.24 |
| Net Debt / FCF Ratio | 0.12 | 0.36 | 1.11 | 1.61 | 0.74 | 2.27 |
| Quick Ratio | 0.93 | 2.17 | 4.70 | 7.04 | 5.54 | 10.63 |
| Current Ratio | 1.48 | 2.62 | 4.97 | 7.19 | 5.91 | 10.95 |
| Return on Equity (ROE) | -255.05% | -230.31% | -101.73% | -112.67% | -71.44% | -78.33% |
| Return on Assets (ROA) | -113.41% | -88.16% | -54.52% | -60.09% | -45.06% | -39.35% |
| Return on Capital Employed (ROCE) | -1,336.00% | -361.30% | -117.90% | -83.40% | -124.00% | -43.00% |
| Earnings Yield | -148.02% | -22.22% | -73.23% | -168.98% | -7.88% | |
| FCF Yield | -356.93% | -150.69% | -19.69% | -59.45% | -208.21% | -9.29% |
| Buyback Yield / Dilution | -71.73% | -31.42% | -39.72% | -186.15% | -220.19% | -558.67% |